Related Experiment Video
Updated: Jun 21, 2026
21:08
Engineering Cell-permeable Protein
Published on: December 28, 2009
Cell engineering and molecular pharming for biopharmaceuticals.
M A Abdullah1, Anisa Ur Rahmah, A J Sinskey
1Department of Chemical Engineering, Universiti Teknologi Petronas, Tronoh, Perak, Malaysia.
The Open Medicinal Chemistry Journal
|August 8, 2009
Summary
This paper reviews biopharmaceutical production using recombinant E. coli and mammalian cells. It covers current methods, advances, and future directions in biomanufacturing, including engineering strategies.
Area of Science:
- Biotechnology
- Biopharmaceutical Manufacturing
Background:
- Biopharmaceuticals are critical therapeutics produced via recombinant DNA technology.
- Common production systems include Escherichia coli (E. coli) and mammalian cell lines, each with distinct pros and cons.
Purpose of the Study:
- To examine current practices, recent developments, and future trends in biopharmaceutical production.
- To review platform technologies for rapid biosystem screening and analysis.
- To highlight strategies for enhancing productivity through metabolic and integrated engineering.
Main Methods:
- Review of existing literature and industry practices in biopharmaceutical manufacturing.
- Analysis of platform technologies for high-throughput screening and biosystem characterization.
- Examination of metabolic engineering and integrated engineering approaches for productivity improvement.
Main Results:
- Discussion of the advantages and disadvantages of different recombinant production systems (E. coli vs. mammalian cells).
- Overview of advancements in screening and analytical technologies for bioprocess development.
- Identification of key engineering strategies to boost biopharmaceutical yields.
Conclusions:
- Biopharmaceutical production relies on optimized recombinant systems, with ongoing innovation in technology and engineering.
- Future trends point towards more efficient and integrated approaches for scalable biomanufacturing.
- Continued development in platform technologies and engineering strategies is crucial for advancing biopharmaceutical production.
More Related Videos
Related Concept Videos
01:27Upstream Processing
Upstream processing represents a critical phase in biomanufacturing, wherein biological systems such as microorganisms, mammalian cells, or insect cells are cultivated to produce therapeutic proteins, vaccines, enzymes, or other biologically derived products. This phase encompasses all steps from the selection and genetic manipulation of the production organism to the cultivation of cells in bioreactors under tightly controlled environmental conditions.Host Selection and Genetic OptimizationThe...
01:30Production of Pharmaceuticals
Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under sterile, tightly...
01:22Bioreactor Controls-III
Strain improvement is a foundational strategy in industrial microbiology aimed at maximizing microbial productivity, particularly because natural isolates typically yield commercially valuable products in very low concentrations. Although optimizing the culture medium and environmental conditions can improve yields, these adjustments are inherently limited by the organism’s genetic potential. As a result, the focus shifts toward genetic modifications to enhance biosynthetic capacity. The...